Respiratory

These findings come as many health care professionals still report limited confidence and inconsistent practices regarding RSV immunization discussions.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Albuterol-budesonide (Airsupra; AstraZeneca) resulted in a 47% reduction in severe exacerbations in mild asthma vs albuterol alone.

Severe RSV disease in 2022–2023 was most likely to occur in infants under 6 months and older children with pulmonary or neurologic conditions.

"Early identification of high-risk neonates may enable targeted strategies to support respiratory health," stated the study investigators.

"These findings support Advisory Committee on Immunization Practices’ recommendations for maternal vaccination or nirsevimab to protect against severe RSV disease in infants," wrote the MMWR study investigators.

On physical examination, the patient appeared to be in significant respiratory distress. Her oxygen saturation was 96% on high-flow nasal cannula.

Current prevention strategies include 2 injectables for infants and young children, namely palivizumab and nirsevimab.

Can you diagnose this patient? Take our poll and find out! Then check back for the full case, differential diagnosis, and correct diagnosis.

Nirsevimab significantly reduces RSV-related hospitalizations, ICU admissions, and LRTIs in infants, but doesn’t shorten hospital stays, according to a recent study.

The World Bank Group reports that as this global health emergency escalates, devastating impacts on health and well-being will also accelerate.

A new study published in JAMA Open Network suggests that early-life exposure to ambient ozone (O3) may contribute to an increased risk of asthma and wheeze in young children.

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the April, 2025, issue of Contemporary Pediatrics, with a special focus on pediatric allergy awareness.

Submission is based on 3 clinical trials, including data from the ApproaCH Trial among children with achondroplasia.

A look ahead to 5 key regulatory decisions scheduled to take place during the second quarter of 2025, from a monoclonal antibody to topical psoriasis treatments.

A presentation at the 46th National Association of Pediatric Nurse Practitioners (NAPNAP) conference explored the role of biologics in pediatric care, their applications in various conditions, and safety considerations for clinicians.

An overview of commercially available infant cardiorespiratory monitors and pulse oximeters in the home.

Study findings underscore the effectiveness of a dual approach to RSV prevention.

Most children with MIS-C recover within 6 months, with heart function and overall health improving significantly, according to a new study.

M pneumoniae infection is not a reportable disease, and testing is often not performed in the outpatient setting, limiting estimates of clinical prevalence and delaying recognition of community epidemics.

Cyclo Therapeutics has enrolled 10 patients in a single-arm sub-study treating newborns to 3 years of age, evaluating the Trappsol Cyclo in the youngest subsets.

Allergic sensitization was more prominent in severe phenotypes but did not explain seasonal differences.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

Can you diagnose this patient?

Editor-in-chief Tina Tan, MD, FAAP, FIDSA, FPIDS, highlights the January/February, 2025, issue of Contemporary Pediatrics.

The patient had increased her vape use recently, but did not disclose when she started, or how much she vaped.

Detectable TTE in children's urine were 'significantly higher' in homes with reported in-home cannabis smoking.

Get caught up with Contemporary Pediatrics! This list helps you navigate our top stories from the week, all in one place.

The study within a single health care system revealed that most infants born prior to December received the nirsevimab monoclonal antibody.

The federal agency has set a target action date of June 10, 2025 for potential approval.